Intellia's Gene-Editing Therapy Achieves 87% Attack Reduction in Phase 3 HAE Trial, BLA Submission Initiated
NTLA sits 99% above its 52-week low of $6.83 on elevated volume (2.2× avg).
Summary
Intellia Therapeutics announced highly positive topline Phase 3 results for its gene-editing therapy, lonvo-z, in hereditary angioedema (HAE). The trial met its primary endpoint, demonstrating an 87% reduction in HAE attacks versus placebo, with 62% of patients achieving attack-free and therapy-free status. The company has initiated a rolling Biologics License Application (BLA) submission to the FDA, aiming for a potential U.S. launch in the first half of 2027. This news follows Intellia's announcement on April 24th that it would report this topline data, making this the highly anticipated release of those results. These strong efficacy and safety data, combined with the BLA submission, represent a significant de-risking event for lonvo-z and validate Intellia's gene-editing platform, marking a major milestone for the company and the broader gene-editing field. Investors will now focus on the BLA review process and the path to commercialization.
At the time of this announcement, NTLA was trading at $13.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.83 to $28.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.